Skip to content Skip to footer
Subscribe Now
Viewpoints_Mina Makar
VIEWPOINTS

A Retrospective Analysis on Cardiac Amyloidosis: Mina Makar from AstraZeneca in an Illuminating Conversation with PharmaShots

Shots:  A UK observational study spanning 17 years shows a 2.9-fold increase in Cardiac Amyloidosis diagnoses, highlighting significant progress in awareness among healthcare professionals and advancements in diagnostic tools  The study underscores the importance of improving the identification and treatment of Cardiac Amyloidosis, particularly in cases with overlapping conditions such as heart failure  Mina Makar,…
February 24, 2025

Read more

Viewpoints_Stephanie Fradette
VIEWPOINTS

Biogen at WMS 2024: Stephanie Fradette from Biogen in an Illuminating Dialogue Exchange with PharmaShots

Shots:  Biogen recently shared findings from the P-II/III DEVOTE study, which investigated the safety and efficacy of a higher dose regimen of Spinraza for the treatment of spinal muscular atrophy (SMA)  Stephanie Fradette, Head of Neuromuscular Development Unit at Biogen, joins PharmaShots for a stimulating conversation on Biogen's groundbreaking presentation at World Muscle Society 2024. …
February 19, 2025

Read more

Viewpoints_Mina Makar
VIEWPOINTS

Curbing Misfolded TTR with RNA Therapy: Mina Makar from AstraZeneca in a Stimulating Conversation with PharmaShots

Shots:  Misfolded TTR can lead to chronic conditions like ATTRv-PN or ATTR-CM. AstraZeneca’s Wainua (eplontersen) is a once-a-month RNA-targeted medication that suppresses TTR production  Mina Makar SVP and Commerical Lead of the Global Cardiovascular, Renal, and Metabolism (CVRM), Biopharmaceuticals Business Unit at AstraZeneca, sheds light on eplontersen and its ongoing P-III clinical trial on ATTR-CM …
February 17, 2025

Read more

Reuters Events Digital Health 2025
EVENTS

Reuters Events: Digital Health 2025

Join us for Reuters Events Digital Health 2025 on 12-13 May in Nashville, where we tackle the critical issues plaguing the healthcare sector today. As organizations face a stretched workforce and an outdated digital infrastructure, the urgency for transformation has never been greater. Current models of care are unsustainable, especially when addressing the diverse needs of an…
February 14, 2025

Read more

Reuters Events Pharma USA 2025
EVENTS

Reuters Events: Pharma USA 2025

Where disruption meets direction  In the past year, pharma has witnessed disruption in the external environment and internal restructure. We’ve reorganized for patients and customers – but it’s one thing to change a job title, another to transform outcomes. But how do you plan for the next wave of change across technology, regulations and expectations? For over…
February 14, 2025

Read more

Viewpoints_Chris Gasink
VIEWPOINTS

Unlocking Approval: Chris Gasink from Johnson & Johnson in an Enlightening Conversation with PharmaShots

Shots: Johnson & Johnson’s (J&J) Tremfya recently received its third approval from the US FDA, supported by the pivotal QUASAR study, which demonstrated significant remission after one year of treatment in adults with moderately to severely active ulcerative colitis Tremfya is a dual-binding monoclonal antibody targeting interleukin 23 (IL-23), a cytokine responsible for inflammation At…
February 3, 2025

Read more

Viewpoints_Dale Curtis Jr
VIEWPOINTS

Intelligent Automation and Beyond: Dale Curtis Jr from Astrix in an Enlightening Conversation with PharmaShots

Shots:  The biopharma industry faces several challenges, including digital transformation, regulatory compliance, and managing large volumes of data  Intelligent automation plays a vital role in drug discovery, clinical trials, manufacturing, and commercialization, helping optimize operations and better meet customer needs  Astrix CEO Dale Curtis Jr. discusses the role of AI and machine learning in global…
January 31, 2025

Read more

Viewpoints_Mina Makar
VIEWPOINTS

Cardiology Care and Beyond: Mina Makar from AstraZeneca in a Riveting Dialogue Exchange with PharmaShots

Shots: At ESC 2024, AstraZeneca presented insights from the real-world OverTTuRe study, exploring the challenges of early diagnosis in transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) Mina Makar, SVP and Commercial Lead of the Global Cardiovascular, Renal, and Metabolism (CVRM) Biopharmaceuticals Business Unit at AstraZeneca, shared real-world insights on how ATTR-CM manifests as cardiac symptoms Mina highlighted the…
January 27, 2025

Read more

Load more